Sonnet Biotherapeutics
Yahoo Finance • 12 days ago
Sonnet to Present at the MedInvest Biotech & Pharma Conference
PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME)... Full story
Yahoo Finance • 2 months ago
Sonnet Releases Virtual Investor "What This Means" Segment
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) - Watch the "What This Means" video here PRINCETON,... Full story
Yahoo Finance • 2 months ago
This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?
Michael Saylor-led MicroStrategy (MSTR) [https://www.barchart.com/quotes/MSTR] started it in 2020. Now, from Tesla (TSLA) [https://www.barchart.com/quotes/TSLA] to Block (XYZ) [https://www.barchart.com/quotes/XYZ] to even the federal gover... Full story
Yahoo Finance • 2 months ago
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a... Full story
Yahoo Finance • 2 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SONN, FCCO, MGRM on Behalf of Shareholders
NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story
Yahoo Finance • 3 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, KLG, MRGM, SONN on Behalf of Shareholders
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story
Yahoo Finance • 3 months ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story
Yahoo Finance • 3 months ago
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has entered into a definitive agreement (the “Business Combination Agreement”, or the “BC... Full story
Yahoo Finance • 3 months ago
Sonnet BioTherapeutics completes $2 million convertible note and warrant sale
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biotech company with a market capitalization of $3.83 million and maintaining more cash than debt on its balance sheet according to InvestingPro data, announced the completion of a pri... Full story
Yahoo Finance • 6 months ago
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with pla... Full story
Yahoo Finance • 6 months ago
Sonnet Announces Release of Corporate Update Video
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME)... Full story
Yahoo Finance • 6 months ago
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME)... Full story
Yahoo Finance • 6 months ago
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechani... Full story
Yahoo Finance • 6 months ago
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18... Full story
Yahoo Finance • 7 months ago
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeu... Full story
Yahoo Finance • 7 months ago
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Poster presented at the 2025 AACR:IO Conference Company’s novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB®) provides enhanced targeting to the tumor mic... Full story
Yahoo Finance • 7 months ago
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Building on proven targeting of the FHAB domain, Sonnet’s ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC construct designated – SON-5010 showed si... Full story
Yahoo Finance • 7 months ago
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has b... Full story
Yahoo Finance • 8 months ago
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of... Full story
Yahoo Finance • 8 months ago
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting... Full story
